About Sun Pharma Advanced Research Company Limited
Data last updated: 14 July 2026
Sun Pharma Advanced Research Company Limited is a public limited company based in Manjusar, Gujarat, India, a subsidiary of Shanghvi Finance Private Limited. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 01 March 2006, the company has been in operation for over 20 years.
Registered with ROC Ahmedabad under CIN L73100GJ2006PLC047837. Listed on BSE: 532872 and NSE: SPARC.
Capital: an authorised share capital of ₹42.5 Cr and a paid-up capital of ₹32.45 Cr. It is led by directors including Rajamannar Thennati and Robert Jay Spiegel.
Last AGM: 12 August 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No. 5 & 6/1 Savli G.I.D.C. Estate Savli – Vadodara Highway, Manjusar, Gujarat, India – 391775.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹1,879.17 Cr, reflecting significant growth compared to the previous year. The net worth stands at ₹1,338.82 Cr (up 717.11% YoY). Total assets are valued at ₹2,170.86 Cr (up 546.99% YoY).
The company has a workforce of approximately 381 employees as per the latest available data. It operates as a subsidiary of Shanghvi Finance Private Limited.
The company is associated with 1 brand - Sparc Life. As per MCA filings, the company has open charges of ₹545 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sparc.life.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressPlot No. 5 & 6/1 Savli G.I.D.C. Estate Savli – Vadodara Highway, Manjusar, Gujarat, India – 391775
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has one previous CIN (Corporate Identification Number): U73100GJ2006PLC047837. The current CIN is L73100GJ2006PLC047837, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L73100GJ2006PLC047837 | Current |
| U73100GJ2006PLC047837 | Previous |
Associated Brands with Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited operates one associated brand: Sparc Life. These brands represent Sun Pharma Advanced Research Company Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Therapies for cancer and inflammatory diseases are developed. | sparc.life |
Competitors & Alternatives of Sun Pharma Advanced Research Company Limited
Brands and companies operating in the same space as Sun Pharma Advanced Research Company Limited include Merck, Roivant Sciences, Amgen and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Merck
|
Pharmaceutical products are manufactured and marketed worldwide. | Kenilworth, United Kingdom, United Kingdom | 1891 |
Roivant Sciences
|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | New York, United States, United States | 2014 |
Amgen
|
Developer of pharmaceutical products for treating multiple diseases | Thousand Oaks, United States, United States | 1980 |
AbbVie
|
Biopharmaceutical research and drug development are conducted globally by AbbVie. | Chicago, United States, United States | 2012 |
Lilly
|
Traditional pharmaceutical medicines are developed for multiple health fields. | United States | 1876 |
Bausch & Lomb
|
Ophthalmic pharmaceuticals and instruments are developed for eye care. | Bridgewater, United States, United States | 1853 |
Roche
|
Pharmaceuticals and diagnostics kits are developed for various diseases. | Basel, Switzerland, Switzerland | 1896 |
Novo Nordisk
|
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. | Bagsvaerd, Denmark, Denmark | 1923 |
Sanofi
|
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | Paris, France, France | 1973 |
GSK
|
Developer of pharmaceuticals and vaccines for various therapeutic areas | Brentford, United Kingdom, United Kingdom | - |
Business Activity of Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | Locked |
Business activity turnover details for Sun Pharma Advanced Research Company Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited is audited by SRBC AND CO LLP (ICAI peer reviewed, certificate valid till 2029-02-28) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| SRBC AND CO LLP (ICAI peer reviewed, certificate valid till 2029-02-28) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited is currently managed by 6 directors, with 16 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajamannar Thennati | Director | 04 Jun 2007 | 19 Years 1 Months | Current |
| Robert Jay Spiegel | Director | 01 Jun 2020 | 6 Years 1 Months | Current |
|
Dilip Shantilal Shanghvi
Also directs:
Sun Pharmaceutical Industries Limited, Sun Petrochemicals Private Limited, Alfa Infraprop Private Limited and 3 more
|
Director | 01 Mar 2006 | 20 Years 4 Months | Current |
|
Venkateswarlu Jasti
Also directs:
Svj Property Holdings Llp, Kj Property Holdings Llp, Js Property Holdings Llp and 5 more
|
Director | 19 May 2025 | 1 Years 2 Months | Current |
| Rekha Gopal Warriar | Director | 19 May 2025 | 1 Years 2 Months | Current |
|
Vidhi Dilip Shanghvi
Also directs:
Sun Pharmaceutical Industries Limited, Sun Petrochemicals Private Limited, Vivaldis Health And Foods Private Limited and 1 more
|
Director | 15 Jul 2024 | 2 Years 0 Months | Current |
Financials of Sun Pharma Advanced Research Company Limited FY 2026 filings available
Sun Pharma Advanced Research Company Limited reported revenue of ₹1,879.17 Cr (up 2518.32% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Revenue from Operations | ₹1,879.17 Cr | ₹71.77 Cr | ₹75.55 Cr |
| Other Income | ₹10.95 Cr | ₹1.79 Cr | ₹29.47 Cr |
| Total Income | ₹1,890.12 Cr | ₹73.56 Cr | ₹105.02 Cr |
| Cost of Materials Consumed | ₹23.6 Cr | ₹23.12 Cr | ₹28.13 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹118.03 Cr | ₹153.58 Cr | ₹141.84 Cr |
| Finance Costs | ₹34.13 Cr | ₹9.04 Cr | ₹1.69 Cr |
| Depreciation & Amortisation | ₹10.21 Cr | ₹12.39 Cr | ₹12.51 Cr |
| Other Expenses | ₹138.78 Cr | ₹218.21 Cr | ₹307.68 Cr |
| Total Expenses | ₹324.75 Cr | ₹416.34 Cr | ₹491.85 Cr |
| Profit Before Exceptional Items & Tax | ₹1,565.37 Cr | -₹342.78 Cr | -₹386.83 Cr |
| Exceptional Items | -₹12.36 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹1,553.01 Cr | -₹342.78 Cr | -₹386.83 Cr |
| Total Tax Expense | -₹19 Lakh | -₹27 Lakh | ₹38 Lakh |
| Net Profit | ₹1,553.2 Cr | -₹342.51 Cr | -₹387.21 Cr |
| attributable to Owners | ₹1,555.77 Cr | -₹342.7 Cr | - |
| attributable to NCI | ₹0 | ₹0 | - |
| Other Comprehensive Income | ₹2.57 Cr | -₹19 Lakh | ₹20 Lakh |
| Total Comprehensive Income | ₹1,555.77 Cr | -₹342.7 Cr | -₹387.01 Cr |
| EBITDA (computed) | ₹1,609.71 Cr | -₹321.35 Cr | -₹372.63 Cr |
| Basic EPS | ₹47.86 | ₹-10.55 | ₹-11.93 |
| Diluted EPS | ₹0.00 | ₹-10.55 | ₹-11.93 |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Total Assets | ₹2,170.86 Cr | ₹335.53 Cr | ₹515.04 Cr |
| Non-current Assets | ₹308.44 Cr | ₹309.34 Cr | ₹245.66 Cr |
| Current Assets | ₹1,862.42 Cr | ₹26.19 Cr | ₹269.38 Cr |
| Property, Plant & Equipment | ₹85.18 Cr | ₹98.7 Cr | ₹107.35 Cr |
| Inventories | ₹0 | ₹0 | ₹0 |
| Trade Receivables | ₹8.27 Cr | ₹16.06 Cr | ₹15.53 Cr |
| Cash & Equivalents | ₹1.16 Cr | ₹1.96 Cr | ₹5.33 Cr |
| Equity (Net Worth) | ₹1,338.82 Cr | -₹216.95 Cr | ₹125.75 Cr |
| Equity Share Capital | ₹32.45 Cr | ₹32.45 Cr | ₹32.45 Cr |
| Borrowings (Non-current) | ₹0 | ₹100 Cr | ₹0 |
| Borrowings (Current) | ₹556.14 Cr | ₹158.19 Cr | ₹47 Cr |
| Total Debt (computed) | ₹556.14 Cr | ₹258.19 Cr | ₹47 Cr |
| Current Liabilities | ₹754.09 Cr | ₹374.24 Cr | ₹265.05 Cr |
| Total Liabilities | ₹832.04 Cr | ₹552.48 Cr | ₹389.29 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Operating Cash Flow | -₹238.77 Cr | -₹360.29 Cr | -₹429.2 Cr |
| Investing Cash Flow | -₹23.5 Cr | ₹157.66 Cr | ₹391.53 Cr |
| Financing Cash Flow | ₹261.39 Cr | ₹199.25 Cr | ₹42.42 Cr |
| Capital Expenditure | ₹23.83 Cr | ₹10.34 Cr | ₹26.51 Cr |
| Free Cash Flow (computed) | -₹262.6 Cr | -₹370.63 Cr | -₹455.71 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹80 Lakh | -₹3.37 Cr | ₹4.75 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,853.22 Cr | ₹8.45 Cr | ₹7.86 Cr | ₹9.64 Cr | ₹27.19 Cr | ₹14.91 Cr | ₹12.86 Cr | ₹16.81 Cr | ₹16.56 Cr | ₹13.86 Cr | ₹21.18 Cr |
| Other Income | ₹1.8 Cr | ₹0 | ₹1 Lakh | ₹9.14 Cr | ₹0 | ₹19 Lakh | ₹4 Lakh | ₹1.56 Cr | ₹4.4 Cr | ₹6.39 Cr | ₹8.49 Cr |
| Total Income | ₹1,855.02 Cr | ₹8.45 Cr | ₹7.87 Cr | ₹18.78 Cr | ₹27.19 Cr | ₹15.1 Cr | ₹12.9 Cr | ₹18.37 Cr | ₹20.96 Cr | ₹20.25 Cr | ₹29.67 Cr |
| Cost of Materials Consumed | ₹5.16 Cr | ₹7.21 Cr | ₹6.1 Cr | ₹5.13 Cr | ₹5.7 Cr | ₹4.58 Cr | ₹8.31 Cr | ₹4.53 Cr | ₹7.46 Cr | ₹9.03 Cr | ₹6.47 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹26.02 Cr | ₹31.18 Cr | ₹29.51 Cr | ₹31.32 Cr | ₹29.85 Cr | ₹30.99 Cr | ₹38.48 Cr | ₹54.26 Cr | ₹50.03 Cr | ₹29.98 Cr | ₹30.71 Cr |
| Finance Costs | ₹11.64 Cr | ₹8.78 Cr | ₹7.52 Cr | ₹6.19 Cr | ₹4.54 Cr | ₹2.8 Cr | ₹1.14 Cr | ₹56 Lakh | ₹91 Lakh | ₹26 Lakh | ₹26 Lakh |
| Depreciation & Amortisation | ₹2.4 Cr | ₹2.57 Cr | ₹2.56 Cr | ₹2.68 Cr | ₹2.95 Cr | ₹3.14 Cr | ₹3.16 Cr | ₹3.14 Cr | ₹3.07 Cr | ₹3.16 Cr | ₹3.18 Cr |
| Other Expenses | ₹48.84 Cr | ₹26.7 Cr | ₹37.97 Cr | ₹25.27 Cr | ₹44.82 Cr | ₹53.03 Cr | ₹68.98 Cr | ₹51.38 Cr | ₹64.9 Cr | ₹77.47 Cr | ₹75.47 Cr |
| Total Expenses | ₹94.06 Cr | ₹76.44 Cr | ₹83.66 Cr | ₹70.59 Cr | ₹87.86 Cr | ₹94.54 Cr | ₹120.07 Cr | ₹113.87 Cr | ₹126.37 Cr | ₹119.9 Cr | ₹116.09 Cr |
| Profit Before Exceptional Items & Tax | ₹1,760.96 Cr | -₹67.99 Cr | -₹75.79 Cr | -₹51.81 Cr | -₹60.67 Cr | -₹79.44 Cr | -₹107.17 Cr | -₹95.5 Cr | -₹105.41 Cr | -₹99.65 Cr | -₹86.42 Cr |
| Exceptional Items | ₹0 | -₹12.36 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1,760.96 Cr | -₹80.35 Cr | -₹75.79 Cr | -₹51.81 Cr | -₹60.67 Cr | -₹79.44 Cr | -₹107.17 Cr | -₹95.5 Cr | -₹105.41 Cr | -₹99.65 Cr | -₹86.42 Cr |
| Total Tax Expense | -₹38 Lakh | ₹7 Lakh | ₹6 Lakh | ₹6 Lakh | -₹90 Lakh | ₹7 Lakh | ₹16 Lakh | ₹40 Lakh | ₹38 Lakh | ₹0 | ₹0 |
| Net Profit | ₹1,761.34 Cr | -₹80.42 Cr | -₹75.85 Cr | -₹51.87 Cr | -₹59.77 Cr | -₹79.51 Cr | -₹107.33 Cr | -₹95.9 Cr | -₹105.79 Cr | -₹99.65 Cr | -₹86.42 Cr |
| attributable to Owners | ₹1,762.69 Cr | - | - | - | -₹60.16 Cr | ₹0 | -₹107.28 Cr | ₹0 | - | -₹99.31 Cr | -₹86.42 Cr |
| attributable to NCI | ₹0 | - | - | - | ₹0 | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 |
| Other Comprehensive Income | ₹1.35 Cr | ₹1.19 Cr | ₹9 Lakh | -₹6 Lakh | -₹39 Lakh | ₹10 Lakh | ₹5 Lakh | ₹5 Lakh | -₹82 Lakh | ₹34 Lakh | ₹34 Lakh |
| Total Comprehensive Income | ₹1,762.69 Cr | -₹79.23 Cr | -₹75.76 Cr | -₹51.93 Cr | -₹60.16 Cr | -₹79.41 Cr | -₹107.28 Cr | -₹95.85 Cr | -₹106.61 Cr | -₹99.31 Cr | -₹86.08 Cr |
| EBITDA (computed) | ₹1,775 Cr | -₹56.64 Cr | -₹65.71 Cr | -₹42.94 Cr | -₹53.18 Cr | -₹73.5 Cr | -₹102.87 Cr | -₹91.8 Cr | -₹101.43 Cr | -₹96.23 Cr | -₹82.98 Cr |
| Basic EPS | ₹54.27 | ₹-2.48 | ₹-2.34 | ₹-1.60 | ₹-1.84 | ₹-2.45 | ₹-3.31 | ₹-2.96 | ₹-3.26 | ₹-3.07 | ₹-2.66 |
| Diluted EPS | ₹0.00 | ₹-2.48 | ₹-2.34 | ₹-1.60 | ₹-1.84 | ₹-2.45 | ₹-3.31 | ₹-2.96 | ₹-3.26 | ₹-3.07 | ₹-2.66 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,879.17 Cr | ₹71.77 Cr | ₹75.55 Cr | ₹238.78 Cr | ₹137.25 Cr | ₹252.96 Cr | ₹76.82 Cr |
| Other Income | ₹10.83 Cr | ₹1.79 Cr | ₹29.47 Cr | ₹10.88 Cr | ₹6.84 Cr | ₹5.41 Cr | ₹9.76 Cr |
| Total Income | ₹1,890 Cr | ₹73.56 Cr | ₹105.02 Cr | ₹249.66 Cr | ₹144.09 Cr | ₹258.37 Cr | ₹86.58 Cr |
| Cost of Materials Consumed | ₹23.6 Cr | ₹23.12 Cr | ₹28.13 Cr | ₹22.11 Cr | ₹18.27 Cr | ₹18.18 Cr | ₹23.92 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹101.85 Cr | ₹108.96 Cr | ₹118.53 Cr | ₹106.99 Cr | ₹96.78 Cr | ₹91.58 Cr | ₹93.09 Cr |
| Finance Costs | ₹34.12 Cr | ₹8.91 Cr | ₹1.66 Cr | ₹7.63 Cr | ₹13.33 Cr | ₹10.65 Cr | ₹2.67 Cr |
| Depreciation & Amortisation | ₹10.07 Cr | ₹10.83 Cr | ₹12.13 Cr | ₹11.77 Cr | ₹10.16 Cr | ₹10.92 Cr | ₹9.48 Cr |
| Other Expenses | ₹155.87 Cr | ₹266.96 Cr | ₹332.68 Cr | ₹323.74 Cr | ₹208.95 Cr | ₹278.18 Cr | ₹269.82 Cr |
| Total Expenses | ₹325.51 Cr | ₹418.78 Cr | ₹493.13 Cr | ₹472.24 Cr | ₹347.49 Cr | ₹409.51 Cr | ₹398.98 Cr |
| Profit Before Exceptional Items & Tax | ₹1,564.49 Cr | -₹345.22 Cr | -₹388.11 Cr | -₹222.58 Cr | -₹203.4 Cr | -₹151.14 Cr | -₹312.4 Cr |
| Exceptional Items | -₹12.36 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1,552.13 Cr | -₹345.22 Cr | -₹388.11 Cr | -₹222.58 Cr | -₹203.4 Cr | -₹151.14 Cr | -₹312.4 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | ₹1,552.13 Cr | -₹345.22 Cr | -₹388.11 Cr | -₹222.58 Cr | -₹203.4 Cr | -₹151.14 Cr | -₹312.4 Cr |
| Other Comprehensive Income | ₹2.07 Cr | -₹25 Lakh | ₹19 Lakh | ₹1.35 Cr | ₹1.7 Cr | ₹1.53 Cr | -₹2.47 Cr |
| Total Comprehensive Income | ₹1,554.2 Cr | -₹345.47 Cr | -₹387.92 Cr | -₹221.23 Cr | -₹201.7 Cr | -₹149.61 Cr | -₹314.87 Cr |
| EBITDA (computed) | ₹1,608.68 Cr | -₹325.48 Cr | -₹374.32 Cr | -₹203.18 Cr | -₹179.91 Cr | -₹129.57 Cr | -₹300.25 Cr |
| Basic EPS | ₹47.83 | ₹-10.64 | ₹-11.96 | ₹-7.82 | ₹-7.73 | ₹-5.77 | ₹-11.92 |
| Diluted EPS | ₹47.83 | ₹-10.64 | ₹-11.96 | ₹-7.82 | ₹7.73 | ₹-5.77 | ₹-11.92 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹2,167.98 Cr | ₹329.29 Cr | ₹486.33 Cr | ₹830.12 Cr |
| Non-current Assets | ₹306.6 Cr | ₹304.02 Cr | ₹239.93 Cr | ₹375.17 Cr |
| Current Assets | ₹1,861.38 Cr | ₹25.27 Cr | ₹246.4 Cr | ₹454.95 Cr |
| Property, Plant & Equipment | ₹85.18 Cr | ₹95.27 Cr | ₹102.46 Cr | ₹105.41 Cr |
| Inventories | ₹0 | ₹0 | ₹0 | ₹0 |
| Trade Receivables | ₹8.27 Cr | ₹16.06 Cr | ₹15.53 Cr | ₹32.71 Cr |
| Cash & Equivalents | ₹32 Lakh | ₹1.19 Cr | ₹5.06 Cr | ₹58 Lakh |
| Equity (Net Worth) | ₹1,333.58 Cr | -₹220.62 Cr | ₹124.85 Cr | ₹512.77 Cr |
| Equity Share Capital | ₹32.45 Cr | ₹32.45 Cr | ₹32.45 Cr | ₹32.45 Cr |
| Borrowings (Non-current) | ₹0 | ₹100 Cr | ₹0 | ₹0 |
| Borrowings (Current) | ₹556.14 Cr | ₹158.19 Cr | ₹47 Cr | ₹5 Lakh |
| Total Debt (computed) | ₹556.14 Cr | ₹258.19 Cr | ₹47 Cr | ₹5 Lakh |
| Current Liabilities | ₹756.82 Cr | ₹373.73 Cr | ₹243.89 Cr | ₹178.94 Cr |
| Total Liabilities | ₹834.4 Cr | ₹549.91 Cr | ₹361.48 Cr | ₹317.35 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹238.89 Cr | -₹362.41 Cr | -₹429.43 Cr | -₹69.12 Cr | -₹208.22 Cr |
| Investing Cash Flow | -₹23.51 Cr | ₹157.66 Cr | ₹391.11 Cr | -₹548.28 Cr | -₹29.17 Cr |
| Financing Cash Flow | ₹261.53 Cr | ₹200.88 Cr | ₹42.8 Cr | ₹616.76 Cr | ₹229.32 Cr |
| Capital Expenditure | ₹23.83 Cr | ₹10.34 Cr | ₹26.51 Cr | ₹15.39 Cr | ₹32.68 Cr |
| Free Cash Flow (computed) | -₹262.72 Cr | -₹372.75 Cr | -₹455.94 Cr | -₹84.51 Cr | -₹240.9 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹87 Lakh | -₹3.87 Cr | ₹4.48 Cr | -₹64 Lakh | -₹8.07 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,853.22 Cr | ₹8.45 Cr | ₹7.86 Cr | ₹9.64 Cr | ₹27.19 Cr | ₹14.91 Cr | ₹12.86 Cr | ₹16.81 Cr | ₹16.56 Cr | ₹13.86 Cr | ₹21.18 Cr | ₹23.95 Cr |
| Other Income | ₹1.8 Cr | ₹0 | ₹1 Lakh | ₹9.02 Cr | ₹0 | ₹19 Lakh | ₹4 Lakh | ₹1.56 Cr | ₹4.4 Cr | ₹6.39 Cr | ₹8.49 Cr | ₹10.19 Cr |
| Total Income | ₹1,855.02 Cr | ₹8.45 Cr | ₹7.87 Cr | ₹18.66 Cr | ₹27.19 Cr | ₹15.1 Cr | ₹12.9 Cr | ₹18.37 Cr | ₹20.96 Cr | ₹20.25 Cr | ₹29.67 Cr | ₹34.14 Cr |
| Cost of Materials Consumed | ₹5.16 Cr | ₹7.21 Cr | ₹6.1 Cr | ₹5.13 Cr | ₹5.7 Cr | ₹4.58 Cr | ₹8.31 Cr | ₹4.53 Cr | ₹7.46 Cr | ₹9.03 Cr | ₹6.47 Cr | ₹5.17 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹21.08 Cr | ₹26.9 Cr | ₹26.19 Cr | ₹27.68 Cr | ₹24.83 Cr | ₹26.41 Cr | ₹28.78 Cr | ₹28.94 Cr | ₹26.72 Cr | ₹29.98 Cr | ₹30.71 Cr | ₹31.12 Cr |
| Finance Costs | ₹11.64 Cr | ₹8.78 Cr | ₹7.52 Cr | ₹6.18 Cr | ₹4.51 Cr | ₹2.77 Cr | ₹1.11 Cr | ₹52 Lakh | ₹88 Lakh | ₹26 Lakh | ₹26 Lakh | ₹26 Lakh |
| Depreciation & Amortisation | ₹2.4 Cr | ₹2.56 Cr | ₹2.57 Cr | ₹2.54 Cr | ₹2.55 Cr | ₹2.75 Cr | ₹2.77 Cr | ₹2.76 Cr | ₹2.69 Cr | ₹3.16 Cr | ₹3.18 Cr | ₹3.1 Cr |
| Other Expenses | ₹54.04 Cr | ₹31.21 Cr | ₹41.46 Cr | ₹29.16 Cr | ₹50.58 Cr | ₹58.3 Cr | ₹79.62 Cr | ₹78.46 Cr | ₹89.9 Cr | ₹77.47 Cr | ₹75.47 Cr | ₹89.84 Cr |
| Total Expenses | ₹94.32 Cr | ₹76.66 Cr | ₹83.84 Cr | ₹70.69 Cr | ₹88.17 Cr | ₹94.81 Cr | ₹120.59 Cr | ₹115.21 Cr | ₹127.65 Cr | ₹119.9 Cr | ₹116.09 Cr | ₹129.49 Cr |
| Profit Before Exceptional Items & Tax | ₹1,760.7 Cr | -₹68.21 Cr | -₹75.97 Cr | -₹52.03 Cr | -₹60.98 Cr | -₹79.71 Cr | -₹107.69 Cr | -₹96.84 Cr | -₹106.69 Cr | -₹99.65 Cr | -₹86.42 Cr | -₹95.35 Cr |
| Exceptional Items | ₹0 | -₹12.36 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1,760.7 Cr | -₹80.57 Cr | -₹75.97 Cr | -₹52.03 Cr | -₹60.98 Cr | -₹79.71 Cr | -₹107.69 Cr | -₹96.84 Cr | -₹106.69 Cr | -₹99.65 Cr | -₹86.42 Cr | -₹95.35 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | ₹1,760.7 Cr | -₹80.57 Cr | -₹75.97 Cr | -₹52.03 Cr | -₹60.98 Cr | -₹79.71 Cr | -₹107.69 Cr | -₹96.84 Cr | -₹106.69 Cr | -₹99.65 Cr | -₹86.42 Cr | -₹95.35 Cr |
| Other Comprehensive Income | ₹1.07 Cr | ₹1.13 Cr | -₹7 Lakh | -₹6 Lakh | -₹39 Lakh | ₹5 Lakh | ₹4 Lakh | ₹5 Lakh | -₹83 Lakh | ₹34 Lakh | ₹34 Lakh | ₹34 Lakh |
| Total Comprehensive Income | ₹1,761.77 Cr | -₹79.44 Cr | -₹76.04 Cr | -₹52.09 Cr | -₹61.37 Cr | -₹79.66 Cr | -₹107.65 Cr | -₹96.79 Cr | -₹107.52 Cr | -₹99.31 Cr | -₹86.08 Cr | -₹95.01 Cr |
| EBITDA (computed) | ₹1,774.74 Cr | -₹56.87 Cr | -₹65.88 Cr | -₹43.31 Cr | -₹53.92 Cr | -₹74.19 Cr | -₹103.81 Cr | -₹93.56 Cr | -₹103.12 Cr | -₹96.23 Cr | -₹82.98 Cr | -₹91.99 Cr |
| Basic EPS | ₹54.26 | ₹-2.48 | ₹-2.34 | ₹-1.60 | ₹-1.88 | ₹-2.46 | ₹-3.32 | ₹-2.98 | ₹-3.29 | ₹-3.07 | ₹-2.66 | ₹-2.94 |
| Diluted EPS | ₹54.26 | ₹-2.48 | ₹-2.34 | ₹-1.60 | ₹-1.88 | ₹-2.46 | ₹-3.32 | ₹-2.98 | ₹-3.29 | ₹-3.07 | ₹-2.66 | ₹-2.94 |
Shareholding Pattern of Sun Pharma Advanced Research Company Limited
As per the shareholding pattern filed with NSE for the quarter ended May 2026, promoters hold 65.67%, foreign institutional investors hold 2.47%, domestic institutional investors hold 0.10%, retail and other public shareholders hold 31.76% of Sun Pharma Advanced Research Company Limited. The company had 137,538 shareholders on record.
| May 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Promoters | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% |
| Public | 34.33% | 34.33% | 34.33% | 34.33% | 34.33% | 34.33% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 65.67% | 65.67% | 65.67% | 65.67% | 69.09% | 68.46% | 68.46% | 68.46% | 67.47% | 66.93% | 67.40% |
| Public | 34.33% | 34.33% | 34.33% | 34.33% | 30.91% | 31.54% | 31.54% | 31.54% | 32.53% | 33.07% | 32.60% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | +0.00 | -3.42 | +0.63 | +0.00 | +0.00 | +0.99 | +0.54 | -0.47 | - |
Board & Governance of Sun Pharma Advanced Research Company Limited
As per the corporate governance filing with NSE for the quarter ended 31-DEC-2025, the board of Sun Pharma Advanced Research Company Limited has 6 directors - 3 independent and 0 executive. The board is chaired by Dilip Shantilal Shanghvi.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Dilip Shantilal Shanghvi | Non-Executive - Non Independent Director · Chairperson | 2006-03-01 | 2 |
| Vidhi Dilip Shanghvi | Non-Executive - Non Independent Director | 2024-07-15 | 2 |
| Rajamannar Thennati | Non-Executive - Non Independent Director | 2007-06-04 | 1 |
| Robert Spiegel | Non-Executive - Independent Director | 2020-06-01 | 1 |
| Venkateswarlu Jasti | Non-Executive - Independent Director | 2025-05-19 | 2 |
| Rekha Gopal Warriar | Non-Executive - Independent Director | 2025-05-19 | 3 |
| Committee | Members |
|---|---|
| Audit Committee | Rekha Gopal Warriar (Chairperson), Venkateswarlu Jasti, Vidhi Dilip Shanghvi, Robert Spiegel |
| Nomination and remuneration committee | Robert Spiegel (Chairperson), Venkateswarlu Jasti, Rekha Gopal Warriar |
| Stakeholders Relationship Committee | Rajamannar Thennati (Chairperson), Vidhi Dilip Shanghvi, Venkateswarlu Jasti |
| Risk Management Committee | Dilip Shantilal Shanghvi (Chairperson), Vidhi Dilip Shanghvi, Rekha Gopal Warriar, Anil Raghavan |
| Corporate Social Responsibility Committee | Dilip Shantilal Shanghvi (Chairperson), Vidhi Dilip Shanghvi, Rekha Gopal Warriar |
Charges & Borrowings of Sun Pharma Advanced Research Company Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Mar 2022 | Others | ₹145 Cr | Open |
| 18 Feb 2021 | Others | ₹400 Cr | Open |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has a workforce of 381 employees as of Apr 08, 2024.
Employee and EPFO history for Sun Pharma Advanced Research Company Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Sun Pharma Advanced Research Company Limited
GST registrations and filing compliance for Sun Pharma Advanced Research Company Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Sun Pharma Advanced Research Company Limited
Credit ratings, litigation, and regulatory alerts for Sun Pharma Advanced Research Company Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Sun Pharma Advanced Research Company Limited
MSME payment history for Sun Pharma Advanced Research Company Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sun Pharma Advanced Research Company Limited
Corporate group structure for Sun Pharma Advanced Research Company Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sun Pharma Advanced Research Company Limited
MCA filings and documents for Sun Pharma Advanced Research Company Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Sun Pharma Advanced Research Company Limited
Recent News on Sun Pharma Advanced Research Company Limited
Frequently Asked Questions about Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited is an active public limited company in the pharma sector based in Manjusar, Gujarat, India. It was incorporated on 01 March 2006 (20+ years old) and is registered under CIN L73100GJ2006PLC047837. Listed on BSE: 532872 and NSE: SPARC. The company has 381 employees.
Sun Pharma Advanced Research Company Limited reported revenue of ₹1,879.17 Cr for FY 2026 (up 2518.32% YoY) based on consolidated NSE filings.
The current directors of Sun Pharma Advanced Research Company Limited are:
- Rajamannar Thennati - Director
- Robert Jay Spiegel - Director
- Dilip Shantilal Shanghvi - Director
- Venkateswarlu Jasti - Director
- Rekha Gopal Warriar - Director
- Vidhi Dilip Shanghvi - Director
The primary industry of Sun Pharma Advanced Research Company Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Sun Pharma Advanced Research Company Limited is listed on both BSE (code: 532872) and NSE (symbol: SPARC).
Sun Pharma Advanced Research Company Limited can be reached at the registered office: Plot No. 5 & 61 Savli G.I.D.C. Estate Savli – Vadodara Highway, Manjusar, Gujarat, India – 391775, or through the website sparc.life.